Successful Treatment with Low-dose Rituximab in a Patient with Plasma Exchange-refractory Idiopathic Thrombotic Thrombocytopenic Purpura / 대한내과학회지
Korean Journal of Medicine
;
: 709-713, 2015.
Artigo
em Coreano
| WPRIM
| ID: wpr-177418
ABSTRACT
Thrombotic thrombocytopenic purpura (TTP) is a clinical syndrome characterized by micro-angiopathic hemolytic anemia, thrombocytopenia, fever, renal disorders, and neurological manifestations. Its clinical course is rapid and the mortality rate is high if untreated or relapse occurs. Previous studies reported that rituximab, a monoclonal antibody for CD20 surface antigen on B lymphocytes, may be effective in treating idiopathic TTP that is refractory to plasma exchange or relapses after remission. A 27-year-old Vietnamese man presented with fever and fatigue starting 3 days earlier, which was diagnosed as idiopathic TTP. To overcome his poor responsiveness to combined therapy using steroids and plasma exchange, rituximab was considered. In the current case, the patient was treated with a lower dose of rituximab, instead of the conventional 375 mg/m2/week, and achieved successful remission.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Plasma
/
Troca Plasmática
/
Púrpura Trombocitopênica Trombótica
/
Recidiva
/
Esteroides
/
Trombocitopenia
/
Linfócitos B
/
Mortalidade
/
Povo Asiático
/
Fadiga
Tipo de estudo:
Estudo prognóstico
Limite:
Adulto
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS